IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
Kuo, Be-Sheng, Li, Chao-Hung, Chen, Jiun-Bo, Shiung, Yu-Yu, Chu, Chia-Yu, Lee, Chih-Hung, Liu, Yaw-Jen, Kuo, Je-Hung, Hsu, Cindy, Su, Hsiao-Wen, Li, Ywan-Feng, Lai, Annie, Ho, Yueh-Feng, Cheng, Yi-Ning, Huang, Hong-Xuan, Lung, Meng-Chung, Wu, Ming-Syue, Yang, Fu-Hung, Lin, Chen-Han, Tseng, William, Yang, Jasper, Lin, Chia-Yin, Tsai, Pei-Hua, Chang, Heng-Kwei, Wang, Yi-Jen, Chen, Techeng, Lynn, Shugene, Liao, Mei-June, Wang, Chang Yi
Published in The Journal of clinical investigation (01.08.2022)
Published in The Journal of clinical investigation (01.08.2022)
Get full text
Journal Article
IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
Be-Sheng Kuo, Chao-Hung Li, Jiun-Bo Chen, Yu-Yu Shiung, Chia-Yu Chu, Chih-Hung Lee, Yaw-Jen Liu, Je-Hung Kuo, Cindy Hsu, Hsiao-Wen Su, Ywan-Feng Li, Annie Lai, Yueh-Feng Ho, Yi-Ning Cheng, Hong-Xuan Huang, Meng-Chung Lung, Ming-Syue Wu, Fu-Hung Yang, Chen-Han Lin, William Tseng, Jasper Yang, Chia-Yin Lin, Pei-Hua Tsai, Heng-Kwei Chang, Yi-Jen Wang, Techeng Chen, Shugene Lynn, Mei-June Liao, Chang Yi Wang
Published in The Journal of clinical investigation (01.02.2023)
Get full text
Published in The Journal of clinical investigation (01.02.2023)
Journal Article